Aytu BioPharma reports Q2 fiscal 2024 operating income of $2.4M, first positive; ADHD revenue up 49%

AYTU BIOPHARMA, INC

2025-Q2 EPS reported -$1.52 vs consensus -$0.04 ▼ miss (-3964.2%)

Consolidated net revenue $22.9M, down 13% YoY due to planned wind-down of Consumer Health Segment.
ADHD Portfolio revenue jumped 49% to $16.6M; Rx Segment gross margin improved to 78% from 72%.
Operating income $2.4M vs. operating loss of $6.9M a year ago; net loss narrowed to $0.2M from $6.7M.
Adjusted EBITDA $5.1M (up 599% YoY); cash $19.5M at Dec 31, 2023.
Company winding down Consumer Health Segment to focus on Rx Segment; expects neutral segment EBITDA for FY2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AYTU BIOPHARMA, INC reported fiscal 2024 second quarter results: revenue $22.9 million, net income $0.2 million, or $0.04 per share, EPS $0.04 per share.

Period: fiscal 2024 second quarter
Revenue: $22.9 million
Net income: $0.2 million, or $0.04 per share
EPS: $0.04 per share
Result: reported results

Exact text from the filing

on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter. Q2 2024 Highlights ● Consolidated net revenue was $22.9 million, compared to $26.3 million in the prior year period. The decrease is primarily due to the planned wind down of the Company's Consumer Health Segment. ● ADHD Portfolio (Adzenys

View on SEC.gov

Browse all earnings releases →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001437749-24-004155

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.